Shanghai Junshi Biosciences Co., Ltd.
Symbol: 1877.HK
HKSE
12.6
HKDMarkedspris i dag
-5.6777
P/E-forhold
0.0426
PEG Ratio
27.42B
MRK Cap
- 0.00%
DIV Udbytte
Shanghai Junshi Biosciences Co., Ltd. (1877-HK) Årsregnskaber
Balance
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 3778.1 | 5996.9 | 3504.6 | ||||||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 341.5 | ||||||||
balance-sheet.row.net-receivables | 0 | 483.2 | 517.7 | 1834.8 | ||||||||
balance-sheet.row.inventory | 0 | 538.1 | 599 | 484.6 | ||||||||
balance-sheet.row.other-current-assets | 0 | 744.4 | 91.3 | 7.7 | ||||||||
balance-sheet.row.total-current-assets | 0 | 5549.8 | 7204.9 | 5831.7 | ||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 4253.3 | 3572 | 3421.3 | ||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||||
balance-sheet.row.intangible-assets | 0 | 134.4 | 110.5 | 51.8 | ||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 134.4 | 110.5 | 51.8 | ||||||||
balance-sheet.row.long-term-investments | 0 | 1133.1 | 1402.8 | 1123.4 | ||||||||
balance-sheet.row.tax-assets | 0 | 103.4 | 228.4 | 88.5 | ||||||||
balance-sheet.row.other-non-current-assets | 0 | 188.4 | 57.6 | 533.9 | ||||||||
balance-sheet.row.total-non-current-assets | 0 | 5812.6 | 5371.4 | 5219 | ||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||
balance-sheet.row.total-assets | 0 | 11362.5 | 12576.3 | 11050.7 | ||||||||
balance-sheet.row.account-payables | 0 | 247.3 | 281.6 | 196.2 | ||||||||
balance-sheet.row.short-term-debt | 0 | 575.3 | 435.4 | 45.1 | ||||||||
balance-sheet.row.tax-payables | 0 | 59.4 | 35.2 | 80.9 | ||||||||
balance-sheet.row.long-term-debt-total | 0 | 1213.2 | 886.2 | 583.1 | ||||||||
Deferred Revenue Non Current | 0 | 181.1 | 121.6 | 118.8 | ||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||||||
balance-sheet.row.other-current-liab | 0 | 7.5 | 1057.2 | 1775.4 | ||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 1547.1 | 1007.8 | 701.9 | ||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||
balance-sheet.row.capital-lease-obligations | 0 | 53.4 | 90.2 | 127.6 | ||||||||
balance-sheet.row.total-liab | 0 | 4022.3 | 2782 | 2718.5 | ||||||||
balance-sheet.row.preferred-stock | 0 | 0.3 | 68.4 | 0 | ||||||||
balance-sheet.row.common-stock | 0 | 985.7 | 982.9 | 910.8 | ||||||||
balance-sheet.row.retained-earnings | 0 | -9040.8 | -6776.6 | -4388.6 | ||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | -142.1 | -68.4 | 0.2 | ||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 15367.7 | 15295.2 | 11438.5 | ||||||||
balance-sheet.row.total-stockholders-equity | 0 | 7170.8 | 9501.4 | 7960.9 | ||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 11362.5 | 12576.3 | 11050.7 | ||||||||
balance-sheet.row.minority-interest | 0 | 169.4 | 292.8 | 371.3 | ||||||||
balance-sheet.row.total-equity | 0 | 7340.2 | 9794.3 | 8332.2 | ||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | ||||||||
Total Investments | 0 | 1133.1 | 1402.8 | 1464.9 | ||||||||
balance-sheet.row.total-debt | 0 | 1788.6 | 1321.6 | 628.2 | ||||||||
balance-sheet.row.net-debt | 0 | -1989.6 | -4675.4 | -2876.4 |
Pengestrømsopgørelse
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |||
---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | -2675.2 | -592.6 | -1669.5 | |||||||
cash-flows.row.depreciation-and-amortization | 0 | 293.7 | 262.6 | 151.4 | |||||||
cash-flows.row.deferred-income-tax | 0 | 0 | -173.8 | -5.7 | |||||||
cash-flows.row.stock-based-compensation | 0 | 91.9 | 192.8 | 30.7 | |||||||
cash-flows.row.change-in-working-capital | 0 | 687.2 | -318.8 | -13.1 | |||||||
cash-flows.row.account-receivables | 0 | 1229.7 | -770.6 | -482.2 | |||||||
cash-flows.row.inventory | 0 | -136.4 | -154.8 | -167 | |||||||
cash-flows.row.account-payables | 0 | -1229.7 | 770.6 | 482.2 | |||||||
cash-flows.row.other-working-capital | 0 | 823.6 | -163.9 | 153.9 | |||||||
cash-flows.row.other-non-cash-items | 0 | -172.9 | -12 | 7.3 | |||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | |||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -394 | -886.2 | -592.7 | |||||||
cash-flows.row.acquisitions-net | 0 | -93.8 | -440.1 | 2.9 | |||||||
cash-flows.row.purchases-of-investments | 0 | -8.5 | -1169.6 | -245.2 | |||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 565.3 | 70.1 | |||||||
cash-flows.row.other-investing-activites | 0 | 28.6 | 49.7 | 66.8 | |||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -467.6 | -1881 | -698 | |||||||
cash-flows.row.debt-repayment | 0 | -113.4 | -793.3 | -401.4 | |||||||
cash-flows.row.common-stock-issued | 0 | 3812.3 | 2150.1 | 4846.9 | |||||||
cash-flows.row.common-stock-repurchased | 0 | 19.2 | 16.7 | 43.2 | |||||||
cash-flows.row.dividends-paid | 0 | -19.2 | -16.7 | -43.2 | |||||||
cash-flows.row.other-financing-activites | 0 | 944.2 | 1308.9 | -32 | |||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 4643 | 2665.7 | 4413.5 | |||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 92.3 | -23.2 | -45.8 | |||||||
cash-flows.row.net-change-in-cash | 0 | 2492.3 | 119.6 | 2171 | |||||||
cash-flows.row.cash-at-end-of-period | 0 | 5996.9 | 3504.6 | 3385 | |||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 3504.6 | 3385 | 1214 | |||||||
cash-flows.row.operating-cash-flow | 0 | -1775.3 | -641.9 | -1498.8 | |||||||
cash-flows.row.capital-expenditure | 0 | -394 | -886.2 | -592.7 | |||||||
cash-flows.row.free-cash-flow | 0 | -2169.3 | -1528.1 | -2091.5 |
Resultatopgørelse række
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 1502.5 | 1453.5 | 4024.8 | ||||||||
income-statement-row.row.cost-of-revenue | 0 | 667.3 | 526.3 | 1258.2 | ||||||||
income-statement-row.row.gross-profit | 0 | 835.3 | 927.2 | 2766.7 | ||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||
income-statement-row.row.research-development | 0 | - | - | - | ||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||
income-statement-row.row.other-expenses | 0 | -35.8 | -34.2 | -91.9 | ||||||||
income-statement-row.row.operating-expenses | 0 | 3287.3 | 3644.2 | 3359.4 | ||||||||
income-statement-row.row.cost-and-expenses | 0 | 3954.6 | 4170.4 | 4617.5 | ||||||||
income-statement-row.row.interest-income | 0 | 99.4 | 61 | 31 | ||||||||
income-statement-row.row.interest-expense | 0 | 29 | 29.4 | 21.8 | ||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||
income-statement-row.row.total-other-income-expensenet | 0 | -15.7 | -3.6 | 92.7 | ||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||
income-statement-row.row.other-operating-expenses | 0 | -35.8 | -34.2 | -91.9 | ||||||||
income-statement-row.row.total-operating-expenses | 0 | -15.7 | -3.6 | 92.7 | ||||||||
income-statement-row.row.interest-expense | 0 | 29 | 29.4 | 21.8 | ||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 303.2 | 293.7 | 262.6 | ||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | ||||||||
income-statement-row.row.operating-income | 0 | -2476 | -2671.6 | -685.3 | ||||||||
income-statement-row.row.income-before-tax | 0 | -2489.9 | -2675.2 | -592.6 | ||||||||
income-statement-row.row.income-tax-expense | 0 | 44 | -93.1 | 135.5 | ||||||||
income-statement-row.row.net-income | 0 | -2281.6 | -2582.1 | -728.2 |
Ofte stillede spørgsmål
Hvad er Shanghai Junshi Biosciences Co., Ltd. (1877.HK) samlede aktiver?
Shanghai Junshi Biosciences Co., Ltd. (1877.HK) samlede aktiver er 11362464000.000.
Hvad er virksomhedens årlige omsætning?
Den årlige omsætning er N/A.
Hvad er virksomhedens profitmargin?
Virksomhedens profitmargin er -0.024.
Hvad er virksomhedens frie pengestrøm?
Det frie cash flow er -2.642.
Hvad er virksomhedens nettoprofitmargin?
Nettofortjenstmargenen er -3.152.
Hvad er firmaets samlede omsætning?
Den samlede omsætning er -3.231.
Hvad er Shanghai Junshi Biosciences Co., Ltd. (1877.HK) nettoresultat (nettoindkomst)?
Nettoresultatet (nettoindkomsten) er -2281624000.000.
Hvad er virksomhedens samlede gæld?
Den samlede gæld er 1788567000.000.
Hvad er tallet for driftsudgifter?
Driftsudgifterne er 3287276000.000.
Hvad er firmaets likviditet?
Virksomhedens likviditet er 0.000.